Mesothelioma

2019 Mesothelioma Treatments in Review

February 26, 2020
Categories: , , ,

There have been many different advances in medicine benefitting mesothelioma patients, and over the course of 2019, different clinical trials have shown that there is still hope for them. One of the clinical trials in 2019 studied Nivolumab, also called Opdivo, as a first- and second-line treatment for mesothelioma. The trial used nivolumab with an…

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors

February 21, 2020
Categories: , ,

The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics of INCB099318 in select solid tumors.

Different Mesothelioma and Cancer Support Groups

February 21, 2020
Categories: , ,

Many times, when people are diagnosed with mesothelioma, they don’t know where to turn. Such a devastating illness can be very isolating and can even cause depression. It might be hard to handle a mesothelioma diagnosis, but people can have hope and support from around the country and even the world. Different online support groups…

Oncolytic Viruses with Standard Chemotherapy can Help Mesothelioma Patients

February 12, 2020
Categories: , ,

Mesothelioma is a cancer with a poor prognosis. People who are diagnosed do not normally have many options, but can at least have hope because of different clinical trials. Clinical trials can help find new treatments and medications to better help mesothelioma sufferers. A clinical trial in Oslo, Norway is looking at oncolytic viruses to…

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors

February 7, 2020
Categories: , ,

The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and early clinical activity of INCB099280 in participants with select solid tumors.

Study of SO-C101 and SO-C101in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumors

January 31, 2020
Categories: , ,

A multicenter open-label phase 1/1b study to evaluate the safety and preliminary efficacy of SO-C101 as monotherapy and in combination with pembrolizumab in patients with selected advanced/metastatic solid tumors

Shorter Survival for Mesothelioma Patients Linked to Specific Biomarker

January 10, 2020
Categories: , , ,

Mesothelioma is a very aggressive cancer with a poor prognosis. When diagnosed, patients can sometimes be given just a few months to live.  Doctors and researchers are continuing to find treatment options to help cure, extend, or at least make patients’ lives better. Some researchers are looking at biomarkers, which can help show doctors what…

Upcoming Mesothelioma Events in 2020

December 27, 2019
Categories: , , , , ,

If you are interested in learning more about mesothelioma, we have a curated list of different events coming up in 2020. If you live near or are able to travel to these events, they can help you and your loved ones understand the disease better. Mayo Clinic Radiation Oncology: Current Practice and Future Direction This…

New Clinical Trial Testing Effectiveness of Immunotherapy and Chemotherapy Before Surgery

December 6, 2019
Categories: , , , , , ,

Mesothelioma, the cancer of the linings of different organs, but primarily the lungs, has a poor prognosis and survival rate for those who are diagnosed. Since there is no cure, treatments helping to extend people’s lives need to be tested. Clinical trials help doctors find new ways to treat mesothelioma and other cancers, possibly extending…

A Feasibility Study Evaluating Surgery for Mesothelioma After Radiation Therapy Using Extensive Pleural Resection (SMARTER)

September 27, 2019
Categories: , , , ,

Primary Outcome Measures Maximum Tolerated Dose for Background Radiation [ Time Frame: Up to five years ]AEs will be graded by CTCAE. Maximum tolerated dose is the dose level that do not result in fatal lung injury (grade 5 lung toxicity) or life-threatening or fatal treatment related toxicity (grade 4+). Secondary Outcome Measures Patient Morbidity [ Time Frame: Up to five years ]NCI…